Business Context and Reporting Period
This summary covers the Form 10-Q for IsoRay, Inc. (Note: The input metadata listed "Perspective Therapeutics," but the filing text identifies the registrant as IsoRay, Inc.) for the quarterly period ended September 30, 2010. IsoRay is a smaller reporting company focused on the development and sale of radioactive seeds for brachytherapy (cancer treatment). The company is currently operating at a loss and is actively seeking capital to maintain its NYSE Amex listing and fund operations.
Key Financial Metrics
| Metric | Q3 2010 | Q3 2009 |
|---|---|---|
| Product Sales (Revenue) | $1,327,127 | $1,379,087 |
| Gross Margin | $215,600 (16.2%) | $218,998 (15.9%) |
| Operating Loss | $(868,480) | $(895,214) |
| Net Loss | $(871,882) | $(906,708) |
| Net Loss Applicable to Common Shareholders | $(874,540) | $(909,366) |
| Cash and Cash Equivalents (End of Period) | $1,024,569 | $3,169,376 |
| Total Assets | $7,042,431 | $7,942,795 (Prior Year End) |
| Total Liabilities | $1,693,840 | $1,746,914 (Prior Year End) |
| Shareholders' Equity | $5,348,591 | $6,195,881 (Prior Year End) |
| Net Cash Used in Operating Activities | $(640,275) | $(515,597) |
Material Changes vs. Prior Period
- Revenue Decline: Product sales decreased by 4% ($51,960) compared to the prior year quarter. This was driven by a reduction in the quantity of seeds sold, partially offset by a 4% increase in the average price per seed. However, revenue from new modalities increased significantly by 193% to approximately $95,064.
- Cost Management: Cost of product sales decreased by 4% ($48,562), aligning with the revenue decline. Gross margin percentage improved slightly from 15.9% to 16.2% due to cost savings in personnel, preload expenses, and depreciation.
- Operating Expenses:
- R&D: Increased 66% ($45,640) due to the addition of a Vice President of R&D and increased labor for brain, breast, and lung cancer development.
- Sales & Marketing: Decreased 16% ($69,474) due to reduced convention, advertising, and share-based compensation expenses.
- G&A: Decreased slightly by 1% ($6,298) due to lower share-based compensation and legal fees, offset by higher audit and tax expenses.
- Liquidity: Cash and cash equivalents dropped significantly from $1.68 million at the end of the prior fiscal year (June 30, 2010) to $1.02 million at September 30, 2010, reflecting a net cash burn of approximately $654,000 for the quarter.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current cash reserves will fund operations only through February 28, 2011. The company does not have sufficient capital to meet requirements for the next twelve months without additional financing.
- Capital Raising: The company plans to raise $2 million to $5 million by December 31, 2010, via equity or debt offerings, likely at a discount to market price. As of November 10, 2010, approximately $564,000 had been raised through "at the market" offerings and warrant exercises.
- Breakeven Targets: Management estimates breakeven requires monthly revenues of approximately $750,000, with cash flow breakeven at $700,000. Current sales levels are insufficient to reach these targets.
- Listing Risk: IsoRay fell below the NYSE Amex minimum stockholder's equity requirement of $6 million (current equity is ~$5.35 million). Failure to raise capital could result in delisting.
- Strategic Focus: The company is expanding into head and neck, colorectal, lung, and brain applications to diversify beyond the prostate market, which faces competition from IMRT and robotics.
- Contingencies: There is an ongoing dispute regarding a "know-how" royalty agreement with the Lawrence Family Trust, though management believes no royalties are currently due. The company also has an asset retirement obligation of $619,115 for radioactive waste disposal.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the projection that cash will last only until February 2011 and the status of the planned $2M-$5M capital raise.
- Listing Status: Monitor the company's progress in raising equity to meet the $6 million NYSE Amex listing requirement to avoid delisting.
- Revenue Mix: Assess the sustainability of the 193% growth in "new modalities" revenue versus the decline in core prostate seed sales.
- Dilution Risk: Review the terms of the "at the market" sales agreement and warrant exercises, as future financing is expected to be dilutive and potentially at a discount.
- Debt Obligations: Confirm the terms of the remaining $168,000 loan with the Hanford Area Economic Investment Fund Committee, including the recent interest rate reduction to 5.5%.